Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis

新兴疗法用于缓解肠道炎症和微生物生态失调，包括益生元和益生菌的饮食供应。消化抗性淀粉（DRS）代表了多种膳食碳水化合物进入下肠道，在那里进行微生物发酵。在过去的几年里，人们一直在研究DRS通过平衡微生物群组成和短链脂肪酸水平对肠道健康的影响。推测DRS可能通过改变肠道菌群、调节局部炎症因子及其对粘膜屏障系统的影响来减轻结肠炎的症状和病理。msprebioinc .是一家总部位于马尼托巴的全球生物技术公司，已开发出一种受欢迎的马铃薯dr产品，名为msprebio®。该公司正在寻求一个项目，以优化其建议的MSPrebiotic®管理作为预防和/或治疗工具，以减少肠道炎症和改善肠道健康。在这里，我们研究了DRS （MSPrebiotic®）对实验性结肠炎猪模型的保护和治疗作用。猪将接受5种不同的处理，包括1)基础对照饲粮，2)诱导结肠炎饲粮（1%卡拉胶），3)DRS饲粮，4)诱导结肠炎饲粮2周后引入DRS饲粮（以测量DRS的治疗效果），5)DRS饲粮2周后引入诱导结肠炎饲粮（以测量DRS的保护作用）。粪便粘稠度和大肠组织学将被用作胃肠道炎症的测量。血液样本将被分析是否有全身性炎症标志物。使用16S rRNA基因测序进行肠道菌群分析，然后使用PICRUSt预测微生物群落的功能能力。这项研究的结果将有助于公司优化他们的建议，使用MSPrebiotic®作为预防和/或治疗方法，以减少肠道炎症和改善肠道健康。

Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietarysupplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietarycarbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has beeninvestigated in the past years for its effects on gut health via balancing the microbiota composition and shortchain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology throughmodification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects onmucosal barrier system.MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRSproduct named MSPrebiotic®. The company is seeking a project to optimize their recommendations foradministration of MSPrebiotic® either as a preventative and/or therapeutic tool for reducing gut inflammationand improving gut health.Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic®) in a pig model ofexperimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducingdiet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRSdiet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (tomeasure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measuresof gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gutmicrobiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction offunctional capacity of the microbial community using PICRUSt. The outcome of this research will help thecompany to optimize their recommendations for the use of MSPrebiotic® as a preventative and/or therapeuticapproach for reducing gut inflammation and improving gut health.